Northwest Bio jumps as Phase III trial keeps on rolling

In contrast to NewLink Genetics ($NLNK), Northwest Biotherapeutics' ($NWBO) interim analysis was a boon to the company's investors, as word that its Phase III trial of a personalized cancer vaccine was going according to plan sent its shares up as much as 10%. In a mid-trial review, Northwest's data monitoring board took a look at safety data from a study on the brain cancer-treating DCVax-L and recommended the trial continue. That cheered investors keeping tabs on the much-watched late-stage study, but the omission of efficacy data--for which a committee review is still pending, according to Northwest--has led some analysts to preach caution. More